Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Top Stories > Dynamk Capital Announces Advisor Dream Team

Dynamk Capital Announces Advisor Dream Team

Published by Gbaf News

Posted on June 20, 2018

5 min read

Last updated: January 21, 2026

Image related to possible misidentification of Azerbaijani plane by Russia - Global Banking & Finance Review — This image highlights the recent U.S. intelligence report regarding Russia's potential misidentification of an Azerbaijani Airlines flight as a drone, leading to a tragic incident in Kazakhstan. It underscores the ongoing complexities in the region amidst the financial implications of military actions.

Dynamk Capital, a venture fund providing early stage and growth capital to innovative Life Science tools and service providers, announces their all-star list of advisors.

Dynamk has paved the way for startups with disruptive technologies and services to gain vital capital to reach the next phase. Dynamk’s partners have leveraged its network of fellow entrepreneurs, industry thought leaders and disrupters in creating a team of advisors to help ensure sound strategic decisions aimed at maximizing returns for investors.

When assembling the team, Dynamk sought domain experts with deep technical knowledge, a proven track record of successful businesses, and most of all, a keen sense of where the industry is trending. The advisor list is a who’s who of widely respected experts in their field:

Kevin Bailey, PhD.; Former VP, Process Development and Preclinical Manufacturing, Regeneron. Kevin brings his experience in preclinical manufacturing and process development areas where he has had extensive experience developing new products, processes and evaluating new technologies.

Barry Buckland, PhD.; CEO, BiologicB, LLC and former VP, Bioprocess R&D, Merck and Co., Inc.. In addition to his years of experience in bioscience and discovery, Barry is a constant source of early stage technologies through his vast industry network and as President of Engineering Conferences International (ECI).
Anthony Maddaluna; Former President, Pfizer Global Supply. Anthony brings his experience in diligence and evaluating the merits of new technologies to be deployed into cGMP manufacturing operations.

Gustavo Mahler, PhD.; CEO, CMC Biologics / AGC Asahi Glass. Gustavo is an expert in biologic development and manufacturing; in his most recent role, he is directly responsible for evaluating and implementing cutting edge technologies.

Barry Buckland commented, “Dynamk Capital has an important role to fill in the Biopharmaceutical industry by making strategic investments to accelerate commercialization of innovative tools and technologies.”

General Partner Daniella Kranjac commented, “The team of advisors will bring insights on best practices and operational excellence needed for early stage companies. They are also well aware of all the key players likely for exiting to and how innovative technologies can fill gaps in their portfolios. This will ensure that companies which are highly likely to succeed are brought into the fund and will be best positioned to exit with maximum returns.”

Kevin Bailey commented, “Dynamk Capital has the rare opportunity to help accelerate research, development and manufacturing in the biopharma industry by identifying companies with disruptive new technologies and facilitating getting them into the hands of those who will bring new products and hope to patients.”

Dynamk Capital, a venture fund providing early stage and growth capital to innovative Life Science tools and service providers, announces their all-star list of advisors.

Dynamk has paved the way for startups with disruptive technologies and services to gain vital capital to reach the next phase. Dynamk’s partners have leveraged its network of fellow entrepreneurs, industry thought leaders and disrupters in creating a team of advisors to help ensure sound strategic decisions aimed at maximizing returns for investors.

When assembling the team, Dynamk sought domain experts with deep technical knowledge, a proven track record of successful businesses, and most of all, a keen sense of where the industry is trending. The advisor list is a who’s who of widely respected experts in their field:

Kevin Bailey, PhD.; Former VP, Process Development and Preclinical Manufacturing, Regeneron. Kevin brings his experience in preclinical manufacturing and process development areas where he has had extensive experience developing new products, processes and evaluating new technologies.

Barry Buckland, PhD.; CEO, BiologicB, LLC and former VP, Bioprocess R&D, Merck and Co., Inc.. In addition to his years of experience in bioscience and discovery, Barry is a constant source of early stage technologies through his vast industry network and as President of Engineering Conferences International (ECI).
Anthony Maddaluna; Former President, Pfizer Global Supply. Anthony brings his experience in diligence and evaluating the merits of new technologies to be deployed into cGMP manufacturing operations.

Gustavo Mahler, PhD.; CEO, CMC Biologics / AGC Asahi Glass. Gustavo is an expert in biologic development and manufacturing; in his most recent role, he is directly responsible for evaluating and implementing cutting edge technologies.

Barry Buckland commented, “Dynamk Capital has an important role to fill in the Biopharmaceutical industry by making strategic investments to accelerate commercialization of innovative tools and technologies.”

General Partner Daniella Kranjac commented, “The team of advisors will bring insights on best practices and operational excellence needed for early stage companies. They are also well aware of all the key players likely for exiting to and how innovative technologies can fill gaps in their portfolios. This will ensure that companies which are highly likely to succeed are brought into the fund and will be best positioned to exit with maximum returns.”

Kevin Bailey commented, “Dynamk Capital has the rare opportunity to help accelerate research, development and manufacturing in the biopharma industry by identifying companies with disruptive new technologies and facilitating getting them into the hands of those who will bring new products and hope to patients.”